Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Cash flows from operating activities
Net income (loss)	$ 483,819	$ (119,891)
Income (loss) from discontinued operations	547,994	(3,698)
Loss from continuing operations	(64,175)	(116,193)
Adjustments to reconcile net loss to net cash used in operating activities
Non-cash interest expense	3,352	4,672
Loss on extinguishment of debt	4,887	14,566
Benefit from intraperiod tax allocation	(32,372)	(9,970)
Depreciation and amortization expense	2,813	4,181
Non-cash activity related to discontinued operations	10,241	9,970
Gain on deconsolidation of Silver Creek Pharmaceuticals, Inc.	(10,848)
Loss (gain) on sale of property and equipment	(439)	187
Stock-based compensation expense	11,110	8,251
Changes in operating assets and liabilities:
Accounts receivable	85	11
Prepaid expenses and other current assets	(6,205)	1,087
Income taxes payable	1,844
Accounts payable, accrued expenses and other	(3,140)	(4,061)
Deferred rent	(334)	493
Net cash used in continuing operations for operating activities	(83,181)	(86,806)
Net cash used in discontinuing operations for operating activities	(37,964)	(52,538)
Net cash used in operating activities	(121,145)	(139,344)
Cash flows from investing activities
Purchase of property and equipment	(729)	(2,868)
Proceeds from maturities and sales of available for sale securities		72,160
Proceeds on sale of property and equipment	1,094
Purchases of available for sale securities		(84,262)
Proceeds from sale of business	575,000
Changes in restricted cash	(60,008)
Net cash provided by (used in) investing activities	511,355	(14,970)
Cash flows from financing activities
Proceeds from exercise of options to purchase common stock	6,517	4,007
Repayment of debt	(175,000)
Payment of dividend	(140,000)
Other financing activities, net		(21)
Net cash provided by (used in) financing activities	(304,489)	5,171
Net increase (decrease) in cash and cash equivalents	85,721	(149,143)
Cash and cash equivalents, beginning of period	21,524	185,606
Cash and cash equivalents, end of period	107,245	36,463
Non-cash investing and financing activities
Purchases of property and equipment in accounts payable, accrued expenses and other	159	105
Receivables related to stock option exercises in prepaid expenses and other current assets		39
Receivables related to property and equipment sale in other current assets	145	40
Transaction costs related to conversion of convertible notes due 2020 in accounts payable, accrued expenses and other		148
Principal amount of convertible notes due 2020 converted into shares of common stock		64,209
Supplemental disclosure of cash flows
Cash paid for income taxes	6,122
Cash paid for interest	30,250	13,851
Silver Creek Pharmaceuticals Inc [Member]
Adjustments to reconcile net loss to net cash used in operating activities
Gain on deconsolidation of Silver Creek Pharmaceuticals, Inc.	(10,848)
Cash flows from investing activities
Deconsolidation of Silver Creek Pharmaceuticals, Inc. cash	(4,002)
Cash flows from financing activities
Proceeds from issuance of Series C preferred stock by Silver Creek Pharmaceuticals, Inc., net of issuance costs	$ 3,994	$ 1,185